$BMY

$ABBV and $BMY deliver above-average dividend yields and growth, standing out as rare healthcare sector exceptions for patient income investors navigating patent cliffs through innovation.

Bristol Myers Squibb's attractive 4.4% dividend yield faces headwinds from major patent expirations on blockbuster drugs Eliquis and Opdivo.

Bristol Myers wins FDA approval for Opdivo plus chemotherapy in untreated Hodgkin lymphoma. Stock declined 1.33% despite clinical success in Study CA209-8UT.

CytomX Therapeutics prices $250M stock offering at $5.30/share to fund Varseta-M development and pipeline advancement, closing March 2026.

Edgewise Therapeutics pursues two major drug candidates addressing unmet cardiac and muscular disease needs, with pivotal data expected through 2026.

Schwab's Dividend ETF ($SCHD) could turn $100 monthly into $67K in 20 years through 13% historical returns and 3.3% dividend yield.

$SCHD ETF offers 3.4% dividend yield from 101 blue-chip stocks with only 8.2% tech exposure, positioning it as a defensive hedge for passive income investors.

BioNTech shares plunge 14% as co-founders announce exit plan, with company cutting 2026 revenue guidance due to declining COVID demand.

Abecma CAR-T therapy market surging on rising myeloma cases and regulatory wins. BMS-backed treatment faces headwinds from tariffs but eyes earlier-line expansion.

Editas Medicine reported Q4 2025 net loss of $5.6M, down 88% YoY. Lead CRISPR therapy EDIT-401 shows >90% LDL-C reduction; IND submission expected mid-2026.

BMY and MDT offer attractive dividend yields and growth potential, with BMY at 4% yield and MDT boasting 48 years of consecutive increases.

Global cytokines market projected to grow from $95.32B (2025) to $174.53B (2032) at 9.02% CAGR, driven by manufacturing advances and strategic partnerships.

$OXB schedules June 2026 Capital Markets Day and four investor conferences, releasing FY2025 results March 26 to boost institutional engagement.

Acute ischemic stroke market poised for significant growth through 2036, driven by novel therapies including recently approved tenecteplase and promising pipeline candidates addressing 1.8 million annual cases.

Bristol Myers Squibb's 4% dividend yield, well above sector averages and trading 25% below 2022 highs, could compound into seven-figure retirement wealth through consistent reinvestment.

Colorectal cancer deaths surge among Americans under 50, becoming the leading cancer killer in this age group. An awareness campaign installs 27,000 blue flags on the National Mall.

BMS's Sotyktu shows promise for psoriatic arthritis among one-third of surveyed rheumatologists, but analysts expect modest market capture ahead of March 2026 FDA decision.

Bristol Myers Squibb's experimental breast cancer drug showed survival improvements in advanced patients, though stock declined slightly following the announcement.

Advanced drug delivery systems market projected to grow from $299.6B (2025) to $487.4B (2030), driven by chronic diseases, nanotechnology breakthroughs, and oncology applications.

Kyverna appoints two biotech executives to its board ahead of cell therapy commercialization. New directors bring expertise from Beam Therapeutics and Karuna Therapeutics.